About APS

For the past 35 years, US pharmaceutical companies have increasingly moved their manufacturing operations overseas to reduce costs. This has created a very dangerous situation for repeated drug shortages that are now being experienced due to COVID-19. According to a June 2020 report by DHS, "Chinese factories that produce raw ingredients for common antibiotics closed for weeks as of March and India's lockdown extended until the end of May." “China has also considered re-imposing lockdown measures as COVID-19 cases have begun to re-emerge." Millions of Americans, including our service members, rely on drug and IV therapies to maintain their health, yet the US is at the mercy of Chinese and Indian manufacturers as well as internal political winds. In an effort to strengthen the American supply chain

and to address these risks, APS is championing the initiative of Made in America – Bring Back API Manufacturing.

So, What is an API?

Active Pharmaceutical Ingredients (APIs) are the active raw materials - used to manufacture Finished Pharmaceutical Products (FPPs). For example, Tylenol contains the API acetaminophen/paracetamol. Global demand for acetaminophen is over 100,000 tons/year. China is the world’s only supplier of this API. The price of acetaminophen API has doubled since the start of the COVID pandemic. This price was rising even before COVID due to an explosion at a production plant in China. APS will enable producers of critical FPPs to manufacture in the USA, without the need to import APIs.

What is APS?

American Pharmaceutical Services (APS) is a newly established American

manufacturer, based in the United States, focused on the creation of active

pharmaceutical ingredients (APIs). The creation of APS will be a major step in making

the United States pharma independent.

Why APS?

The APS team will be managed by seasoned professionals possessing over 100+ years

of collective experience in pharmaceutical and medical device manufacturing, with responsibilities for the launch of over 20 new drugs, 50+ generic drugs (with a total sales of over $300 billion) and more than 200 different generic APIs.

The founders and Advisors of APS are strongly positioned to build a company that can capture a substantial share of the US API market. These individuals have a wealth of hands-on experience in API manufacturing, regulation, quality assurance, and the US/global supply chain and markets.

We know the competition for API production in the US and globally. We know the raw

materials markets and suppliers. We know API sales and marketing. The founders of APS have a strong record of innovation in API synthesis and technologies. For instance, every day approximately 24 million people throughout the world with AIDS take drugs containing APIs made by processes developed or improved by APS scientists.